# US 2018/0021364 A1 · Central nervous system targeting polynucleotides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021364 A1
- Document ID: US20180021364A1
- Status: Published application
- Kind: A1
- Application number: 15/543,773
- Filed: 2016-01-15
- Published: 2018-01-25
- Earliest claimed: 2015-01-16
- Assignees: Voyager Therapeutics, Inc.
- Applicants: Voyager Therapeutics, Inc.
- Inventors: Gregory Robert Stewart; Dinah Wen-Yee Sah; Jinzhao Hou; Adrian Philip Kells; Martin Goulet; Kartik Ramamoorthi; Pengcheng Zhou; Yanqun Shu
- Web page: https://patentgrep.com/patent/US20180021364A1

## CPC

- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- A61K 48/0083: {characterised by an aspect of the administration regime}
- C07K 14/47: from mammals
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides encoding payloads for the treatment of CNS disorders.

## Claims

### Claim at position 1

1-2. (canceled)

### Claim 3 (depends on 7)

The polynucleotide of claim 7, wherein the polynucleotide comprises at least one 5′ inverted terminal repeat (ITR), one 3′ inverted terminal repeat ITR, a promoter region, and an enhancer, and wherein said enhancer is a CMV enhancer.

### Claim 4 (depends on 3)

The polynucleotide of claim 3, wherein the open reading frame encoding human frataxin is codon optimized.

### Claim at position 4

5-6. (canceled)

### Claim 7

A polynucleotide encoding human frataxin comprising a sequence having at least 95% identity to a sequence selected from the group consisting of SEQ ID NOs 1-94 or variants thereof.

### Claim 8 (depends on 7)

The polynucleotide of claim 7, comprising a sequence having at least 99% identity to a sequence selected from the group consisting of SEQ ID NOs 1-94 or variants thereof.

### Claim 9

A polynucleotide comprising a sequence selected from the group consisting of SEQ ID NOs 1-94, wherein the frataxin payload is replaced by gene encoding a CNS protein of interest or a modulatory nucleic acid.

### Claim 10 (depends on 9)

The polynucleotide of claim 9, wherein the polynucleotide has at least 95% identity to a sequence selected from the group consisting of SEQ ID NOs 1-94 or variants thereof.

### Claim 11

(canceled)

### Claim 12 (depends on 7)

An AAV particle comprising the polynucleotide of claim 7 packaged in a capsid, said capsid having a serotype selected from the group consisting of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV9.47, AAV9(hu14), AAV10, AAV11, AAV12, AAVrh8, AAVrh10, AAV-DJ and AAVDJ8.

### Claim at position 11

13-18. (canceled)

### Claim 19 (depends on 18)

The method of claim 18, wherein the polynucleotide in packaged in an AAV particle, said AAV particle comprising a capsid having a capsid serotype selected from the group consisting of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV9.47, AAV9(hu14), AAV10, AAV11, AAV12, AAVrh8, AAVrh10, AAV-DJ and AAVDJ8.

### Claim at position 13

20-24. (canceled)

### Claim 25 (depends on 26)

The method of claim 26, wherein increasing the level of protein treats a disease or disorder, wherein the disease or disorder is Friedreich's Ataxia.

### Claim 26

A method of increasing the level of a protein in the CNS of a subject in need thereof comprising administering to said subject via prolonged infusion an effective amount of an AAV particle comprising a viral genome encoding a sequence selected from the group consisting of SEQ ID NOs 1-94 or a therapeutically effective amount of a polynucleotide comprising a sequence selected from the group consisting of SEQ ID NOs 1-94 wherein the frataxin payload has been replaced by gene encoding a CNS protein of interest or a modulatory nucleic acid.

### Claim 27 (depends on 26)

The method of claim 26, wherein the prolonged infusion is by intracerebroventricular (ICV) administration.

### Claim 28 (depends on 26)

The method of claim 26, wherein the prolonged infusion is by injection into the ventricular system of the brain.

### Claim 29 (depends on 28)

The method of claim 28, wherein the injection to the ventricular system occurs in at least one location selected from the group consisting of the right lateral ventricle, left lateral ventricle, third ventricle, fourth ventricle, interventricular foramina (also called the foramina of Monro), cerebral aqueduct, central canal, median aperture, right lateral aperture, and left lateral aperture, perivascular space.

### Claim at position 19

30-32. (canceled)

### Claim 33 (depends on 26)

The method of claim 26, wherein the prolonged infusion is by intrathecal (IT) administration.

### Claim 34 (depends on 33)

The method of claim 33, wherein IT administration occurs by injection into the subarachnoid space, and wherein the injection into the subarachnoid space occurs in at least one location selected from the group consisting of the cervical, thoracic, lumbar and sacral regions of the spine, wherein if the injection occurs in the cervical region the injection occurs in a location selected from the group consisting of C1, C2, C3, C4, C5, C6, and C7, wherein if the injection occurs in the thoracic region the injection occurs in a location selected from the group consisting of T1, T2, T3, T3, T4, T5, T6, T7, T8, T9, T10, T11, and T12, wherein if the injection occurs in the lumbar region the injection occurs in a location selected from the group consisting of L1, L2, L3, L4, and L5, and wherein if the injection occurs in the sacral region the injection occurs in a location selected from the group consisting of S1, S2, S3, S4 and S5.

### Claim at position 22

35-41. (canceled)

### Claim 42 (depends on 26)

The method of claim 26 wherein the prolonged infusion occurs at a volume selected from the group consisting of, a volume of more than 1 mL, a volume of less than 1 mL, a volume between about 0.1 mL to about 120 mL, a volume of at least 3 mL, a volume of 3 mL, a volume of at least 10 mL, and a volume of 10 mL.

### Claim at position 24

43-48. (canceled)

### Claim 49 (depends on 26)

The method of claim 26, wherein the prolonged infusion occurs for at least a duration selection from the group consisting of 0.17, 0.33, 0.5, 0.67, 0.83, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, and 36 hour(s).

### Claim at position 26

50-53. (canceled)

### Claim 54 (depends on 26)

The method of claim 26, wherein the prolonged infusion occurs at a constant rate.

### Claim 55 (depends on 26)

The method of claim 26, wherein the prolonged infusion occurs at a ramped rate.

### Claim 56 (depends on 55)

The method of claim 55, wherein the ramped rate increases over the duration of the prolonged infusion.

### Claim 57 (depends on 26)

The method of claim 26, wherein the prolonged infusion occurs at a complex rate alternating between high and low rates over the duration of the prolonged infusion.

### Claim 58

(canceled)

### Claim 59 (depends on 26)

The method of claim 26, wherein prolonged infusion occurs at a rate between about 0.1 mL/hour and about 25.0 mL/hour, wherein the rate of prolonged infusion is selected from the group consisting of 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10.0, 10.1, 10.2, 10.3, 10.4, 10.5, 10.6, 10.7, 10.8, 10.9, 11.0, 11.1, 11.2, 11.3, 11.4, 11.5, 11.6, 11.7, 11.8, 11.9, 12.0, 12.1, 12.2, 12.3, 12.4, 12.5, 12.6, 12.7, 12.8, 12.9, 13.0, 13.1, 13.2, 13.3, 13.4, 13.5, 13.6, 13.7, 13.8, 13.9, 14.0, 14.1, 14.2, 14.3, 14.4, 14.5, 14.6, 14.7, 14.8, 14.9, 15.0, 15.1, 15.2, 15.3, 15.4, 15.5, 15.6, 15.7, 15.8, 15.9, 16.0, 16.1, 16.2, 16.3, 16.4, 16.5, 16.6, 16.7, 16.8, 16.9, 17.0, 17.1, 17.2, 17.3, 17.4, 17.5, 17.6, 17.7, 17.8, 17.9, 18.0, 18.1, 18.2, 18.3, 18.4, 18.5, 18.6, 18.7, 18.8, 18.9, 19.0, 19.1, 19.2, 19.3, 19.4, 19.5, 19.6, 19.7, 19.8, 19.9, 20.0, 20.1, 20.2, 20.3, 20.4, 20.5, 20.6, 20.7, 20.8, 20.9, 21.0, 21.1, 21.2, 21.3, 21.4, 21.5, 21.6, 21.7, 21.8, 21.9, 22.0, 22.1, 22.2, 22.3, 22.4, 22.5, 22.6, 22.7, 22.8, 22.9, 23.0, 23.1, 23.2, 23.3, 23.4, 23.5, 23.6, 23.7, 23.8, 23.9, 24.0, 24.1, 24.2, 24.3, 24.4, 24.5, 24.6, 24.7, 24.8, 24.9, and 25.0 mL/hour.

### Claim at position 33

60-62. (canceled)

### Claim 63 (depends on 26)

The method of claim 26, wherein administration comprises a total dose between about 1×106 VG and about 1×1016 VG, wherein the total dose is selected from the group consisting of about 1×106, 2×106, 3×106, 4×106, 5×106, 6×106, 7×106, 8×106, 9×106, 1×107, 2×107, 3×107, 4×107, 5×107, 6×107, 7×107, 8×107, 9×107, 1×108, 2×108, 3×108, 4×108, 5×108, 6×108, 7×108, 8×108, 9×108, 1×109, 2×109, 3×109, 4×109, 5×109, 6×109, 7×109, 8×109, 9×109, 1×1010, 2×1010, 3×1010, 4×1010, 5×1010, 6×1010, 7×1010, 8×1010, 9×1010, 1×1011, 2×1011, 3×1011, 4×1011, 5×1011, 6×1011, 7×1011, 8×1011, 9×1011, 1×1012, 2×1012, 3×1012, 4×1012, 5×1012, 6×1012, 7×1012, 8×1012, 9×1012, 1×1013, 2×1013, 3×1013, 4×1013, 5×1013, 6×1013, 7×1013, 8×1013, 9×1013, 1×1014, 2×1014, 3×1014, 4×1014, 5×1014, 6×1014, 7×1014, 8×1014, 9×1014, 1×1015, 2×1015, 3×1015, 4×1015, 5×1015, 6×1015, 7×1015, 8×1015, 9×1015, and 1×1016 VG.

### Claim at position 35

64-67. (canceled)

### Claim 68 (depends on 26)

The method of claim 26, wherein the prolonged infusion comprises a composition concentration between about 1×106 VG/mL and about 1×1016 VG/mL of AAV comprising at least one polynucleotide encoding a payload, wherein the concentration is selected from the group consisting of 1×106, 2×106, 3×106, 4×106, 5×106, 6×106, 7×106, 8×106, 9×106, 1×107, 2×107, 3×107, 4×107, 5×107, 6×107, 7×107, 8×107, 9×107, 1×108, 2×108, 3×108, 4×108, 5×108, 6×108, 7×108, 8×108, 9×108, 1×109, 2×109, 3×109, 4×109, 5×109, 6×109, 7×109, 8×109, 9×109, 1×1010, 2×1010, 3×1010, 4×1010, 5×1010, 6×1010, 7×1010, 8×1010, 9×1010, 1×1011, 2×1011, 3×1011, 4×1011, 5×1011, 6×1011, 7×1011, 8×1011, 9×1011, 1×1012, 2×1012, 3×1012, 4×1012, 5×1012, 6×1012, 7×1012, 8×1012, 9×1012, 1×1013, 2×1013, 3×1013, 4×1013, 5×1013, 6×1013, 7×1013, 8×1013, 9×1013, 1×1014, 2×1014, 3×1014, 4×1014, 5×1014, 6×1014, 7×1014, 8×1014, 9×1014, 1×1015, 2×1015, 3×1015, 4×1015, 5×1015, 6×1015, 7×1015, 8×1015, 9×1015, and 1×1016 VG/mL.

### Claim at position 37

69-78. (canceled)

### Claim 79 (depends on 26)

The method of claim 26, further comprising co-administration of intravenous mannitol.

### Claim 80

(canceled)

### Claim 81 (depends on 79)

The method of claim 79, wherein a dose of approximately 0.25 to 1.0 g/kg intravenous mannitol is co-administered, and wherein the dose of intravenous mannitol is selected from the group consisting of 0.25, 0.26, 0.27, 0.28, 0.29, 0.30, 0.31, 0.32, 0.33, 0.34, 0.35, 0.36, 0.37, 0.38, 0.39, 0.40, 0.41, 0.42, 0.43, 0.44, 0.45, 0.46, 0.47, 0.48, 0.49, 0.50, 0.51, 0.52, 0.53, 0.54, 0.55, 0.56, 0.57, 0.58, 0.59, 0.60, 0.61, 0.62, 0.63, 0.64, 0.65, 0.66, 0.67, 0.68, 0.69, 0.70, 0.71, 0.72, 0.73, 0.74, 0.75, 0.76, 0.77, 0.78, 0.79, 0.80, 0.81, 0.82, 0.83, 0.84, 0.85, 0.86, 0.87, 0.88, 0.89, 0.90, 0.91, 0.92, 0.93, 0.94, 0.95, 0.96, 0.97, 0.98, 0.99, and 1.00 g/kg.

### Claim at position 41

82-88. (canceled)

### Claim 89 (depends on 26)

The method of claim 26 wherein the AAV comprises a capsid selected from the group consisting of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAVrh8, AAVrh10, AAV-DJ, and AAV-DJ8.

### Claim 90 (depends on 89)

The method of claim 89, wherein the AAV comprises a self-complementary (SC) genome.

### Claim 91 (depends on 89)

The method of claim 89, wherein the AAV comprises a single stranded (SS) genome.

### Claim at position 45

92-93. (canceled)

### Claim 94 (depends on 26)

The method of claim 26, wherein the subject is in a position selected from the group consisting of horizontal for the duration of the prolonged infusion, vertical for the duration of the prolonged infusion, at an angle between approximately horizontal 0° to about vertical 90° for the duration of the prolonged infusion, the position of the subject changes during the duration of the prolonged infusion from horizontal to vertical, and the position of the subject changes during the duration of the prolonged infusion from vertical to horizontal.

### Claim at position 47

95-101. (canceled)
